A multicenter, randomized, double-blind clinical study on Weifuchun for the prevention and treatment of colorectal adenomas.

INTERVENTION: Experimental Group:Weifuchun Capsule;Control Group:Wei Fuchun Capsule Simulator; CONDITION: Colorectal adenoma PRIMARY OUTCOME: Adenoma recurrence rate;TCM Syndrome Score; SECONDARY OUTCOME: Carcinoembryonic Antigen (CEA), Carbohydrate Antigen 19‐9 (CA19‐9), Carbohydrate Antigen 72‐4 (CA72‐4), Carbohydrate Antigen 242 (CA242), Fecal Occult Blood Test (FOBT), Fecal Immunochemical Test (FIT);Asia‐Pacific Colorectal Cancer Screening Score;SF‐36 Health Survey;SAS Anxiety Scale SDS Depression Scale;Polyp detection rate; INCLUSION CRITERIA: (1) Aged between 18 and 65 years, with no gender restriction; (2) Underwent endoscopic resection within 90 days prior to enrollment, with histopathological confirmation of colorectal adenoma (tubular adenoma, villous adenoma, or mixed adenoma); (3) Single colorectal adenoma measuring =10 mm in size, or multiple adenomas (=2) with at least one measuring =5 mm; (4) No participation in any relevant drug clinical trials and no history of related medication use within 90 days before screening; (5) Good patient compliance, able to understand the study and sign the informed consent form.